Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis - 16/03/14
Kenneth Gordon, MD, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States; Craig Leonardi, MD, St. Louis University School of Medicine, St. Louis, MO, United States; Daniel Braun, MD, Eli Lilly and Company, Indianapolis, IN, United States; Gregory Cameron, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Janelle Erickson, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Mark Lebwohl, MD, The Mount Sinai School of Medicine, New York, NY, United States; Michael Heffernan, MD, Eli Lilly and Company, Indianapolis, IN, United States; Subhashis Banerjee, MD, Eli Lilly and Company, Indianapolis, IN, United States
Le texte complet de cet article est disponible en PDF. Sponsored 100% by Eli Lilly and Company. |
Vol 70 - N° 5S1
P. AB183 - mai 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?